结直肠癌中ABCG2表达与伊立替康为基础化疗疗效相关性研究

  目的   明确结直肠癌组织中ABCG2（ATP-binding cassette superfamily G member 2，ABCG2）的表达及其与患者临床病理特征、以伊立替康（CPT-11）为基础化疗疗效的相关性，从而为结直肠癌患者实现个体化治疗提供理论依据。   方法   筛选1996年1月至2011年12月于北京大学肿瘤医院行CPT-11化疗的晚期结直肠癌患者，收集患者完整病史资料及肿瘤组织样本。用免疫组织化学的方法检测样本中ABCG2蛋白表达情况。分析ABCG2蛋白表达与患者临床病理特征、CPT-11化疗疗效的相关性。   结果   1）免疫组织化学染色显示ABCG2在结直肠癌组织中表达阳性率达93.2%，癌旁正常肠黏膜ABCG2蛋白阳性表达率为43.6%，癌组织较癌旁正常黏膜组织的表达水平明显增高（P < 0.05）。ABCG2表达与患者年龄、性别、病理分化程度、病变部位、肝转移均无明显相关性。2）ABCG2蛋白表达与CPT-11化疗疗效无显著相关（P>0.05）。   结论   在应用伊立替康为基础方案化疗的结直肠癌患者中，癌组织中ABCG2蛋白表达水平与患者化疗疗效无明显相关。 

Correlation of ABCG2 expression with the efficacy of irinotecan chemotherapy in colorectal cancer patients

  Objective   To identify the ABCG2 expression levels in colorectal cancer patients and its relationship with clinicopathological features and the efficacy of irinotecan-based chemotherapy and to provide further theoretical basis for individualized treatment.   Methods   Clinical data and tumor samples from patients with metastatic CRC who have received irinotecan-based chemotherapy at the Department of Gastroenterological Oncology, Peking University Cancer Hospital from January 1996 to December 2011 were collected. The immunohistochemical method was used to detect ABCG2 expression levels both in colorectal carcinoma and tumor-adjacent normal tissues. The correlations of the expression of ABCG2 with clinicopathological features and the efficacy of irinotecan-based chemotherapy were statistically analyzed.   Results   1) Immunohistochemical staining shows that the positive rate of ABCG2 expression in the colorectal cancer samples is 93.2%, which is significantly higher than that in normal colon mucosa at 43.6% (P < 0.05). No significant associations were observed between ABCG2 expression and age, gender, tumor differentiation, primary tumor sites, or liver metastasis.(2) ABCG2 expression has no significant correlation with the efficacy of irinotecan-based chemotherapy (P>0.05).   Conclusion   ABCG2 expression has no significant correlation with the efficacy of irinotecan chemotherapy in patients with colorectal cancer.